Metformin as maintenance therapy in bone sarcomas at high risk of relapse

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515639-32-00

Acronym

Metformina-Bone

Enrollment

Registered

2024-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone sarcoma

Brief summary

Event Free Survival

Detailed description

unexpected metformin toxicity, patient therapy compliance with EORTC QLQ-C30 questionnaire

Interventions

DRUGMETFORMIN

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Event Free Survival	—

Secondary

Measure	Time frame
unexpected metformin toxicity, patient therapy compliance with EORTC QLQ-C30 questionnaire	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026